APOE and Alzheimer disease: However, since these clinical samples are derived from symptomatic individuals or asymptomatic individuals who may harbor subclinical AD pathology, it remains unclear whether this APOE ε4 immune phenotype precedes or follows the development of AD pathology, a critical question for guiding diagnosis and treatment in APOE ε4 carriers.